罗格列酮对内皮祖细胞增殖、黏附及迁移能力的影响

目的：观察罗格列酮（rosiglitazone,Ros）对体外培养内皮祖细胞（endothelial progenitor cells,EPCs）增殖、黏附及迁移能力的影响。方法：以密度梯度离心法获取脐血单个核细胞,培养7d后收集贴壁细胞并分为正常对照组、单独Ros（1μmol/L、5μmol/L及10μmol/L）组、H2O2（500μmol/L）氧化应激模型组、Ros（1μmol/L、5μmol/L及10μmol/L）和H2O2共同干预组,培养24h。用流式细胞仪检测细胞表达CD34、CD133、VEGFR-2、VE-Cadherin并用荧光显微镜观察细胞吞噬DiI-ac-LDL和FITC-UEA-1来鉴定EPCs。分别用CCK-8、普通光学倒置显微镜、改良的Boyden小室检测EPCs的增殖、黏附和迁移能力。结果：与正常对照组相比,单独Ros干预组呈浓度依赖性促进脐血来源的EPCs增殖、黏附及迁移能力（均P〈0.05）,但是Ros5μmol/L和10μmol/L组间没有显著差异（P〉0.05）;与H2O2氧化应激损伤组相比,Ros能呈浓度依赖性改善H2O2对EPCs增殖、黏附及迁移功能的抑制（均P〈0.05）,Ros5μmol/L和10μmol/L干预保护组之间没有显著差异（均P〉0.05）。结论：噻唑烷二酮（TZDs）类药物Ros除具有激动PPAR-γ受体降糖作用外,还具有抗氧化应激损伤作用。Ros能促进EPCs功能,改善H2O2致EPCs功能的氧化应激损伤。

Effect of rosiglitazone on ability of proliferation, conglutination and transfere of endothelial progenitor of cells in vitro

Objective: To study the effect of rosiglitazone on the ability of proliferation, conglutination and transfere of endothelial progenitor cell in vitro. Methods: Total mononuclear cells were isolated from the umbilical cord blood with ficoll density gradient centrifugation, after the redblood cells were precipitated by hydroxyethyl starch, and cultured in vitro. Cells were cultured for 7 days, which expressed CD34/CD133/VEGFR-2/VE-Cadherin tested by flow cytometry and ability of intaking DIL-ac-LDL and FITC-UEA-1 tested under fluorescence microscope were identified as EPCs. EPCs were determined after treatment with rosiglitazone (1, 5, 10 mmol/L) alone and in the presence of H2O2 (500 umol/L) for 24 h. EPCs' functions were assayed with CCK-8, Boyden cabin, and adherent cells were counted under inverted microscope. Results: Compared to the control group, rosiglitazone groups, concentration dependence improved cells' function(sP<0.05), there was no significant difference between rosiglitazone 5 mmol/L group and 10 mmol/L grou(pP>0.05). In the same versus to the H2O2 group rosiglitazone groups concentration-dependent protected EPCs from oxidative stress(P<0.05). Conclusion: Rosiglitazone has other effect of anti-oxidative stress beside euglycemic agent on EPCs. Rosiglitazone concentration-dependent promotes EPCs' functions and improves the injury of oxidative stress caused by H2O2.